Welcome to our dedicated page for NEPHROS SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nephros Inc. filings document formal disclosures for a water technology company selling filtration solutions to medical and commercial markets. Recent 8-K reports furnish operating results and financial condition updates, Regulation FD presentations, and material event disclosures tied to the company's product, service, and education strategy.
The filing record also includes a material definitive agreement with Medica S.p.A. covering license and supply arrangements for filtration products based on Medisulfone ultrafiltration technology. These disclosures describe contractual rights, supply obligations, product commercialization arrangements, and related public-company reporting matters.
Lisa Nettis, a director of Nephros Inc. (NEPH), acquired 13,229 stock options on 08/11/2025 with an exercise price of $4.49 per share. The options convert into 13,229 shares of common stock and have an expiration date of 08/11/2035.
The filing discloses a vesting schedule: 4,410 options vest on each of 6/16/2025 and 6/16/2026, and 4,409 vest on 6/16/2027. The Form 4 was executed by Edward Peilen as attorney-in-fact on 08/13/2025 and lists Nettis as a director.
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.